Calycosin (Isoflavone · Pro-angiogenic · Phytoestrogenic)

Compound	Calycosin
Chemical class	Polyphenol — Isoflavone (3′-Hydroxyformononetin)
CAS	20575-57-9
Primary source	Astragalus membranaceus (Huang Qi / Astragalus root)
Key applications	Pro-angiogenic, phytoestrogenic, cardiovascular
Claim strength	Moderate
Typical form	Astragalus root extract co-constituent
Buy from Herbuno	Cycloastragenol 98% Powder (Astragalus Root) | High-Purity Isolate | Astragalus membranaceus → Polysaccharides 70% Powder (Huang Qi Extract) | Standardized Astragalus membranaceus →

Name origin: From Calycosin — identified in Astragalus and related leguminous plants. Structurally, calycosin is 3′-hydroxyformononetin (formononetin with an additional 3′-hydroxyl on the B-ring), placing it in the isoflavone class with slight structural differentiation from the red clover isoflavones. Traditional use: Astragalus root (Huang Qi) is one of the most important tonic herbs in TCM, prescribed for qi deficiency, immune support, cardiovascular protection, and as a general adaptogen. Calycosin is a key isoflavone bioactive within Astragalus root extracts, alongside the better-known astragalosides (triterpene saponins). Research trajectory: Calycosin has attracted research attention for its pro-angiogenic properties (relevant to wound healing and cardiac ischaemia recovery), phytoestrogenic activity, and cardiovascular effects. Much of the evidence comes from Chinese pharmacology research. Commercial source: Calycosin is commercially available as a co-constituent of Astragalus membranaceus root extract. High-purity cycloastragenol (98%) and polysaccharide-standardised Astragalus extracts co-deliver calycosin as part of the full phytochemical matrix. See sourcing options below.

---

Evidence for Calycosin Applications

Pro-angiogenic and cardioprotective: Calycosin promotes angiogenesis (new blood vessel formation) via VEGF and eNOS pathway activation in endothelial cell models and in vivo ischaemia models. In cardiac ischaemia-reperfusion models, calycosin reduces infarct size and promotes neovascularisation in the peri-infarct zone. This is a mechanistically interesting property for cardiac recovery and wound healing formulations. Claim strength: Moderate (preclinical; TCM clinical data supporting Astragalus for cardiovascular; calycosin-specific clinical data limited).

Phytoestrogenic and bone-protective: Calycosin binds ERβ preferentially and stimulates osteoblast differentiation in cell models. In ovariectomised rat models, calycosin preserves bone mineral density. These effects are consistent with its structural similarity to formononetin and daidzein. Claim strength: Moderate.

Anti-inflammatory and immunomodulatory: Calycosin suppresses NF-κB, reduces macrophage pro-inflammatory cytokine production, and modulates T-cell activity in immune cell models. Consistent with Astragalus root’s broad immunomodulatory TCM profile. Claim strength: Moderate.

---

Dosage & Formulator Specification

No established clinical dose for isolated calycosin. Astragalus root TCM doses: 9–30 g dried root/day as decoction. Commercial Astragalus extract doses for immune/cardiovascular support: 500–1500 mg/day standardised extract. Calycosin content in Astragalus extracts is rarely specified but present as a co-constituent alongside astragalosides, formononetin, and polysaccharides.

For formulations seeking calycosin activity, specify Astragalus membranaceus root extract with HPLC profile including calycosin alongside the primary markers (astragaloside IV, cycloastragenol). Calycosin quantification confirms authentic Astragalus membranaceus source versus substituted or adulterated materials.

Calycosin has low aqueous solubility (isoflavone class). Standard capsule/tablet formats appropriate. No dedicated bioavailability enhancement studies for calycosin; Astragalus extract matrix may provide mild solubilisation.

---

Frequently Asked Questions — Calycosin

Is calycosin the primary bioactive in Astragalus root?
No. Astragalus root has a complex phytochemical profile; the primary commercially targeted actives are the astragalosides (particularly astragaloside IV and cycloastragenol, its aglycone) for telomere and immune applications. Calycosin is a secondary bioactive that contributes isoflavone/phytoestrogenic and cardiovascular activity to the overall Astragalus profile.

Can calycosin from Astragalus be positioned for women’s health formulations?
Yes — Astragalus root extract’s calycosin content provides a rationale for women’s health positioning alongside the adaptogenic and immune benefits. Astragalus is a more multi-benefit ingredient than isolated isoflavones; the phytoestrogenic activity of calycosin is a secondary rather than primary positioning point for Astragalus extract.

Is calycosin unique to Astragalus or present in other supplement botanicals?
Calycosin is present in several leguminous plants (Astragalus, Desmodium, Caragana spp.). Among commonly used supplement ingredients, Astragalus membranaceus is the most commercially relevant source. It can also be detected in trace amounts in red clover and some other isoflavone-containing botanicals.

Does calycosin’s pro-angiogenic activity raise safety concerns?
The pro-angiogenic properties are relevant in the context of ischaemia recovery and wound healing — both beneficial contexts. In oncology contexts, pro-angiogenic compounds theoretically could support tumour vascularisation. Standard advisory language for immune-modulatory botanicals should include a recommendation for consultation with an oncologist for individuals with active cancer. This is standard practice for Astragalus products generally.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery